pathological complete response even after NACT. [11] [12] [13] [14] Epigenetic modulations are some of the key players in deciding the drug tolerating ability of the cancer cells. 15, 16 But the actual mechanism of chemotherapeutic tolerance of BC is not well understood.
Tolerance or resistance to drug treatments may occur due to mismatch repair (MMR), pathway inactivation, and some chemotherapeutic drugs trigger cell-cycle arrest in G2 in an MMR-dependent manner. 17 MLH1 and MSH2 are the most important genes in the MMR pathway. 18 Both genetic and epigenetic alterations of MLH1
and MSH2 contribute to genomic instability and tumorigenesis in sporadic BC. 19 Varying frequency of deletion and methylation (11% to 45%) of MLH1 and MSH2 has been reported in primary BC. [20] [21] [22] [23] [24] [25] Reduced expression of MLH1 and MSH2 proteins has been reported in 27% to 31% sporadic BC. 25, 26 To the best of our knowledge, 
| MATERIALS AND METHODS

| Demography of the clinical specimens
Freshly operated 45 NACT-treated and 133 pretherapeutic primary BC samples, adjacent normal tissues, along with 5 mL blood of the corresponding patients were collected from 178 unrelated patients from the hospital section of Chittaranjan National Cancer Institute (CNCI), Kolkata. NACT-treated samples were operated after 2 to 6 months of NACT treatment. Informed consent from the patients and approval from the Research Ethics Committee of the Institute were obtained prior sample collection. All tumors were staged according to the International Union against Cancer (UICC) tumornode-metastasis (TNM) classification. Molecular subtyping of the samples based on ER, PR, and HER2 status was done by immunohistochemistry using specific antibodies sc-787, sc-7208, and sc-7301, respectively, of Santa Cruz Biotechnology (Santa Cruz, CA). 9 In NACT-treated samples, the frequencies of luminal A, luminal B, HER2-enriched, and TNBC subtypes were 31%, 27%, 11%, and 31%, respectively, whereas, in pretherapeutic BC samples, their frequencies were 22%, 26%, 31%, and 21%, respectively (Supporting Information Tables S1A and S1B ). Detailed clinicopathological information like stage/grade/nodal status/age of onset/molecular subtypes are listed in Supporting Information Table S1 . Sample distribution of the patients' tumor samples for different experiments were given in Supporting Information Figure S1 . 
| Cell culture
| Deletion analysis
Deletion analysis of MLH1 and MSH2 genes was done by microsatellite-based deletion mapping. 27 Deletion mapping of MLH1 locus was done using the microsatellite marker D3S1611
and for MSH2, microsatellite markers D2S123 and D2S391 were used. A standard polymerase chain reaction (PCR) was carried out by using a γ[p32] ATP-labeled forward primer. PCR products were electrophoresed on 7% denaturing polyacrylamide sequencing gel and autoradiographed. 27 Loss of heterozygosity (LOH) was scored to 
| Promoter methylation analysis
Promoter methylation analysis of MLH1 and MSH2 genes was performed to study the epigenetic alterations. Promoter methylation status of MLH1 and MSH2 was analyzed in CpG-rich islands in the promoter region of the respective genes by PCR-based methylationsensitive restriction analysis (MSRA) using HpaII (Promega, Fitchburg, WI), Msp1 and Hha1 (Sibenzyme, Novosibirsk, Russia) enzymes. 29 The β-3A adaptin gene (K1) and RARβ2 (K2) were used as digestion and integrity controls, respectively. 30 The primer sequences are listed in Supporting Information Table S2C .
Quantification of promoter methylation was done by real-time PCR using a power SYBR-Green assay (Applied Biosystems). 31 Figure S2A ). 32 According to this protocol, a 28S/18S ratio greater than two means the purified total RNA is of high quality. RNA quality, along with 28S/18S ratio are given in Supporting Information Figure S2B . Quantitative real-time PCR (qRT-PCR) of the candidate tumor suppressor gene (TSGs) was performed using a power SYBR-green assay (Applied Biosystems) with b2-microglobulin as a control. 33, 34 Each sample was loaded in triplicate and run at 40 cycles on an ABI prism 7500 machine (Applied Biosystem). The primer sequences are listed in Supporting Information Western blot analysis MCF-7 and MDA MB 231 cells were lysed by sonication with radioimmunoprecipitation assay buffer as described by Sur et al. 36 Proteins (80 µg) were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to polyvinylidinedifluoride membrane (Millipore, Burlington, MA). To reduce nonspecific binding, membranes were incubated with 3% nonfat dry milk for 1 to 2 hours at room temperature. Membranes were then incubated overnight at 4°C with desired MLH1 and MSH2 primary antibodies (as mentioned above at dilution of 1:500-1:1000 in 1% nonfat dry milk) followed by corresponding HRP-conjugated secondary antibodies (1:2000-1:10 000 in 1% nonfat dry milk). The target protein bands were then visualized using luminal reagent and autoradiographed on X-ray film (Kodak, Rochester, NY). All the immunoblotting experiments were performed in three replicates. The band intensities were quantified using a densitometric scanner (GS-800; BioRad Hercules, CA). Peak densities of the proteins of interest were normalized using peak density of loading control α-tubulin. For immunocytochemistry, fluorescein isothiocyanate-conjugated secondary antibodies were used and 4′,6-diamidino-2-phenylindole was used to stain the nucleus (Santa Cruz Biotechnology). 36 DNA was isolated for methylation analysis of MLH1/MSH2 promoters as described earlier.
| Statistical analysis
Fisher's exact test was used for the analysis of contingency table to find the differences among proportions. Survival analysis was done using the 3 | RESULTS
| Alterations of MLH1 and MSH2 in NACT-treated BC samples
To understand the roles of MLH1 and MSH2 in chemotolerance of BC, the alterations (deletion/methylation) of these genes were studied in NACT-treated BC samples. In allelotyping of MLH1 and MSH2 loci deletion, MAI and MAII were seen in the samples ( Figure 1A -C). Deletion frequencies of MLH1 and MSH2 loci were 38% and 34%, respectively, seen in the samples ( Figure 1D ). However, infrequent (3% to 4%) MAI and MAII in MLH1/MSH2 loci were observed (Supporting Information   Table S3 ). Differential deletion frequencies were found in different subtypes of the samples ( Figure 1D ). The deletion of MLH1 was significantly low (P = 0.027) in luminal B than HER2-enriched subtype. A similar trend was also observed in MSH2 with a low deletion in TNBC.
The MLH1 and MSH2 loci showed 31% to 39% deletion in the early and late age of onset BC ( Figure 1E) . Interestingly, about 50% of the NACT samples showed deletion in at least one of the locus and codeletion of the loci was found in 9% of the samples (Supporting Information Table S3 ).
The promoter regions of MLH1/MSH2 genes have multiple HpaII/ HhaI sites ( Figure 1F ) and showed methylation in different samples ( Figure 1G ). Frequent methylation (49%-51%) of MLH1/MSH2
promoters was found in the NACT-treated samples ( Figure 1H ).
Differential methylation frequencies (36%-64%) of MLH1/MSH2
were also found in different subtypes of the samples ( Figure 1H ). The methylation frequencies of the genes were in the range of 38%-62%
in early and late age of onset BC ( Figure 1I ). Interestingly, 71% of the NACT samples showed promoter methylation in at least one of the genes and comethylation was found in 29% of the samples (Supporting Information Table S3 ).
High frequencies (62%-64%) of overall alterations (deletion/ methylation) of MLH1 and MSH2 were seen in the NACT-treated BC samples with differential (57%-80%) alterations in different subtypes ( Figure 1J ). Comparable frequencies (54%-76%) of overall alteration of MLH1 and MSH2 were seen in early and late age of onset BC ( Figure 1K ). About 82% of the NACT samples showed an overall alteration in at least one of the genes and coalteration was found in 44% of the samples (Supporting Information Table S3 ). Table S3 ). However, low frequency (12%-13%) of deletion was seen in luminal A in both the loci with significant (P = 0.012 to 0.031) increase in HER2 and/or TNBC subtypes ( Figure   2A ). The MLH1 and MSH2 loci showed comparable deletion frequencies (30%-39%) in the early and late age of onset BC ( Figure   2B ). Like NACT samples, 50% of the pretherapeutic samples showed deletion in at least one of the locus and codeletion of the loci was found in 7% of the samples (Supporting Information Table S3 ).
Similar to the NACT samples, comparable methylation frequencies of MLH1 and MSH2 promoters were found in 62% and 41%, respectively, in pretherapeutic samples ( Figure 2C ). The comparatively high frequency of methylation was seen in MLH1 (52%-71%) than MSH2 (28%-50%) in the different subtypes ( Figure 2C ). High frequency of methylation of MLH1
(60%-67%) was seen in both early-and late-onset BC, whereas, DASGUPTA ET AL. *Significant difference in alteration of the genes; P < 0.05 was considered to be statistically significant. BC, breast carcinoma; NACT, neoadjuvant chemotherapy methylation of MSH2 was significantly high (P = 0.033) in early-onset BC (53%) than late-onset (34%) ( Figure 2D ). Like NACT samples, 79% of the pretherapeutic samples showed promoter methylation in at least one of the genes and comethylation was found in 23% of the samples (Supporting Information Table S3 ).
High frequencies (58%-71%) of overall alterations (deletion/ methylation) of MLH1 and MSH2 were seen in the pretherapeutic samples ( Figure 2E ). The frequencies of alterations of MLH1/MSH2 were significantly high in TNBC subtype than luminal A (P = 0.004-0.026; Figure 2E ). Overall alterations of MLH1 and MSH2 were seen in 53% to 76% in the early and late age of onset BC ( Figure 2F ). Similar to the NACT samples, 87% of the pretherapeutic samples showed overall alterations in at least one of the genes and coalteration was found in 41% of the samples (Supporting Information Table S3 ). Figure S4A and S4B). At 20-µM 5-aza-dC treatment, increase in expression of MLH1 was 1.9-2 fold in the cell lines, whereas, MSH2 expression was highly increased in MCF-7 (5.8-fold) and MDA MB 231 (2.9-fold). This indicates that promoter methylation is one of the inactivation mechanisms of these genes in BC. Figure 3C and 3D) . Reduced or absence of expression of MLH1 and MSH2 proteins was seen in 43% to 52% of the NACT-treated and 51% to 53% of pretherapeutic BC samples having a concordance (P < 0.001-0.004) with the molecular alterations (Supporting Information Table S4A and S4B).
| Validation of promoter methylation in BC cell lines
| Expression analysis of MLH1 and MSH2 in BC samples
| Association of the alterations with clinicopathological parameters and survival
No significant changes in the frequencies of overall alteration were found in different clinicopathological parameters like a clinical stage, grade, and nodes at pathology (Supporting Information Figure S5A-F) .
The pretherapeutic BC patients with alterations in MLH1 and/or MSH2 showed significantly poor DFS but no such association was seen in NACT-treated patients (Supporting Information Figure S6A-F) .
| Changes in the profiles of MLH1 and MSH2 genes in BC cell lines after treatment with anthracycline antitumor antibiotics
To understand the association of MLH1 and MSH2 genes with chemotolerance in BC cells, the viability of MCF-7 and MDA MB 231 was analyzed at first in the presence of doxorubicin and nogalamycin followed by analysis of RNA/protein expression and methylation profile of the genes.
| Cell viability and expression analysis
The IC 50 concentrations of doxorubicin and nogalamycin in MCF-7 and MDA MB 231 cells were in the range from 0.214 to 0.37 µM (Supporting Information Figure S7A and S7B).
Initially, the mRNA expression of MLH1 and MSH2 genes were analyzed in the BC cell lines after the treatment of three different doses of the drugs (Figure 4A-F) . In MCF-7 cell line, significantly high In Western blot analysis, the MLH1 and MSH2 protein expression in presence of the drugs showed concordance with mRNA expression ( Figure 5A and 5B). Increased expression of MLH1 and MSH2 proteins was observed at different concentrations of the drugs in both the cell lines ( Figure 5A and 5B). The expression of these proteins in most was significantly high (1.267-6.397 fold) in the lower IC 50 Immunocytochemical analysis also showed concordance with the mRNA expression ( Figure 5C ). The expression of MLH1 and MSH2 was mainly present in the nuclear membrane of MCF-7 cells with diffused cytoplasmic and nuclear expression in absence of the drugs.
At low concentration of the drugs (lower IC 50 ), high nuclear expression of the proteins was seen followed by a gradual decrease in expression pattern with an increase in drug concentrations.
Interestingly, at high concentration (higher IC 50 ) of the drugs the expression of the proteins was predominantly seen in the nuclear periphery ( Figure 5C ). Similar patterns of expression were also found in MDA MB 231 cells (data not shown).
| Promoter methylation analysis in chemotolerant BC cells
To understand the molecular mechanism behind the increased expression of MLH1/MSH2 genes in presence of the drugs (doxorubicin/nogalamycin), the promoter methylation status of the genes analyzed in both the cell lines. No qualitative differences in methylation patterns of the genes were seen compared with the respective controls after drug treatment (data not shown). But, in quantitative PCR analysis of methylation, mostly significantly increased frequencies of hypomethylation of the promoters of MLH1 and MSH2 genes were observed with different concentrations of the drugs in both the cell lines, irrespective of the restriction enzymes used (P < 0.0001; Figure   6A -H). In MCF-7, increased frequencies of hypomethylation were observed at the lower IC 50 (0.1 µM) concentration of the drugs (Figure 6A-D) . However, with increased drug concentration (IC 50 and higher IC 50 ), the frequencies of hypomethylation of the genes were high or comparable with the control (Figure 6A-D) . In the case of MDA MB 231, the frequencies of hypomethylation of the genes were comparable or high at the different concentrations of the drugs than the control (Figure 6E-H) . The hypomethylation patterns of the genes in presence of the drugs showed concordance with respective mRNA expression patterns. In NACT samples, the deletion and methylation frequencies of MLH1/MSH2 genes were 34%-51% with prevalent methylation (49%-51%) than deletion (34%-38%). The overall alteration (deletion/ methylation) of these genes was high (62%-64%) in the samples irrespective of different subtypes. To the best of our knowledge, the alterations of NACT-treated BC samples were not reported earlier. In | 97 pretherapeutic samples, a similar trend in deletion and methylation patterns were seen with 32% to 62% alterations. The overall alteration of MLH1/MSH2 genes was also high (58%-71%) in the pretherapeutic samples with significantly high alteration in TNBC than luminal A in pretherapeutic samples. Similar frequencies of deletion and methylation were reported in these loci in other reports on BC. [20] [21] [22] [23] [24] [25] In our previous studies on head and neck squamous cell carcinoma (HNSCC) and cervical cancer, 27% to 46% deletion and 13% to 42% methylation was observed in MLH1. 38, 39 About, 23% to 42% deletion was reported in lentigo maligna and malignant melanomas in MLH1/MSH2 loci. 38 In HNSCC, 50% of tumors harbored methylation at either or both MLH1
and MSH2 promoters. 40 Methylation of MLH1/MSH2 genes was also associated with colorectal cancers and lung cancers. [41] [42] [43] In pretherapeutic BC, TNBC showed the highest deletion but in NACT-treated samples, HER2-enriched type showed the highest deletion hinting toward the differences in the pathogenesis of the molecular subtypes of BC. Our study showed NACT-treated and pretherapeutic samples reported in BC. 25, 26 Similarly, in colon cancers, 33% to 50% reduced expression of MLH1 and MSH2 proteins were reported. 42 Alterations of these genes showed worst patient outcome in pretherapeutic samples, suggesting prognostic importance, whereas, in NACT-treated BC, no significant association of patients' survival with the alterations in these genes was found instead of a similar pattern of alterations of the genes. This might be due to the low proliferation index and low stem-cell prevalence in NACT-treated samples than pretherapeutic samples as seen in our previous study. and induce the expression of these genes particularly in nucleus for efficient repair. 44 Induction of the DNA-damage response proteins by the chemotherapeutic drugs were reported in different cancers along with BC. [45] [46] [47] Interestingly, at lower IC 50 concentration, the localization of the proteins predominantly in the nuclear periphery might be due to some posttranslational modification of these proteins. 48 This increased expression of these genes in presence of the drugs was due to their promoter hypomethylation as seen in our quantitative methylation analysis. A similar phenomenon of high promoter hypomethylation of the genes was also evident in NACT-treated BC samples than pretherapeutic samples. It was evident that the mismatch repair genes were mainly involved in DNA repair during replication errors in the Sphase of the cell cycle. Thus, it seems that the replication errors in chemotolerant BC cells might have overcome by the upregulation of the mismatch repair genes resulting survival of the cells escaping the druginduced DNA-damage-associated apoptosis. A similar phenomenon has also been seen in homologous recombination repair genes in chemotolerant BC as seen in our previous study. 9, 49 In addition, the hypomethylation of the genes in presence of the drugs might be due to the inhibition/reduced expression of the DNA-methylating enzymes like DNA methyltransferase 1 (DNMT1) as seen in our previous study. 49 Doxorubicin-induced inhibition of DNA methyltransferase 1 (DNMT1) has been reported in colon carcinoma cell line. 50 Thus, our study showed increased expression of MLH1/MSH2 due to their promoter hypomethylation might be an important phenomenon in chemotolerance of BC.
